In the late 1990s, treatments like Prozac and research on the human genome project appeared to usher in a new human reality with associated bioethical dilemmas. Are bioethicists as likely to be co-opted into the marketing of the new neuroscience and its treatments as they were into the marketing of the SSRIs? Contrasting current neuroimaging with quantitative electroencephalography, recent deep brain stimulation treatments...
Read the rest of the story HERE:
Comments
The time limit for entering new comments on this Quicklink has expired.
